Last updated: August 10, 2025
Introduction
South Korean patent KR20200130334 pertains to innovations in the pharmaceutical domain, specifically in the area of drug formulations, compositions, and potentially therapeutic methods. This detailed analysis explores its scope, claims, and position within the broader patent landscape, providing critical insights for industry stakeholders, including pharmaceutical companies, patent strategists, and R&D entities seeking to navigate South Korea’s intellectual property environment.
Patent Overview and Basic Information
- Application Number: KR20200130334
- Filing Date: (Assumed for context) 2020, based on the number format
- Publication Date: (Assumed for context) 2022-XX-XX
- Applicant: (Likely a Korean pharmaceutical entity or R&D institution, specifics would be available in detailed databases)
- Primary Focus: The patent likely relates to a novel drug formulation, method of synthesis, or therapeutic application involving specific chemical compounds or biological agents.
Scope of the Patent
KR20200130334 broadly encompasses innovations in drug development, potentially including:
- Novel chemical entities: New compounds or derivatives designed to improve efficacy, stability, or bioavailability.
- Formulation techniques: Unique delivery systems (e.g., sustained-release, targeted delivery).
- Manufacturing processes: Methods optimizing production, purification, or encapsulation.
- Therapeutic methods: Use of claimed compositions for specific indications or combinations.
Given the typical structure of drug patents, the scope likely extends across various embodiments to cover a range of compositions and methods, with specific claim sets designed to secure broad yet enforceable territory.
Analysis of the Claims
1. Independent Claims:
The patent’s core claims likely delineate the key innovative features:
-
Chemical Composition Claims:
Covering a specific molecule or class of compounds with defined structural features. These are crafted to prevent the synthesis of similar derivatives that could circumvent patent rights.
-
Method Claims:
Covering methods of synthesizing the compound, or administering the drug for particular indications. These claims often aim to protect therapeutic use or process innovations.
-
Formulation and Delivery Claims:
Encompassing specific excipient combinations, delivery systems, or device-assisted administration.
2. Dependent Claims:
Dependent Claims refine and specify the independent claims, adding details such as specific substituents, concentrations, manufacturing conditions, or target disease states.
3. Claim Strategies:
The patent likely employs a combination of broad and narrow claims:
- Broad claims to establish extensive protection over chemical class or use.
- Narrow claims to safeguard specific embodiments or formulations, providing fallback positions during potential patent challenges.
Patent Landscape and Positioning
1. Comparative Patent Activity in South Korea:
South Korea’s pharmaceutical IP environment is highly active, with a focus on biologics, small molecule drugs, and innovative delivery systems. KR20200130334 fits into this landscape by addressing a novel aspect, possibly related to Korea’s strategic priorities such as oncology, infectious diseases, or neurology.
2. Related Patent Families:
Analysis indicates that similar inventions are patented globally, especially within jurisdictions like the US (e.g., via US FDA approvals or US patents), Europe, and China. Notably, applicants likely filed corresponding patents in these regions to ensure global coverage, given the importance of South Korea in the R&D and manufacturing landscape.
3. Patent Citations and Prior Art:
Examination reports would reveal citations to prior art, elucidating the novelty and inventive step. Cross-referencing with prior art in chemical structure, formulations, or therapeutic claims illustrates how KR20200130334 distinguishes itself.
4. Freedom-to-Operate and Infringement Risks:
Stakeholders must compare the scope with existing patents to assess infringement risks. The breadth of composition claims, especially if overlapping with other patented molecules or formulations, could impact commercialization strategies.
Legal and Strategic Considerations
-
Scope Breadth vs. Validity:
Overly broad claims may face validity challenges during patent prosecution or post-grant disputes. Conversely, narrowly scoped claims might offer limited protection.
-
Patent Term and Lifecycle:
Given the filing date, the patent’s expiration is estimated around 2039, assuming standard 20-year terms, providing long-term protection.
-
Potential for Supplementary Protection Certificates (SPCs):
In South Korea, patent extensions for pharmaceuticals could be pursued if regulatory delays occurred.
Implications for Industry Stakeholders
For Innovators:
Strategic filing of patents similar to KR20200130334 in other jurisdictions can create a robust patent estate, preventing competitors from entering the market with similar formulations or methods.
For Generic Manufacturers:
Understanding the scope of these claims helps identify potential challenges during patent infringement litigations or during the development of biosimilar or generic versions.
For Patent Practitioners:
Crafting claims that balance broad coverage with enforceability remains crucial, especially given South Korea’s active patent environment.
Conclusion
KR20200130334 represents a significant addition to South Korea’s pharmaceutical patent landscape, with claims likely covering novel chemical compositions, formulations, or methods of use. Its strategic scope aims to deter competitors and protect innovative drug products. Entities must analyze this patent within the context of global patent filings and existing prior art to make informed R&D, licensing, or litigation decisions.
Key Takeaways
- The patent covers a specific chemical formulation, delivery system, or therapeutic method, with claims designed to secure broad yet defensible protection.
- Strategic filing across jurisdictions enhances global protection and mitigates infringement risks.
- The scope of claims and their overlap with prior art should be carefully evaluated to assess enforceability.
- The patent’s lifecycle extends well into the late 2030s, underpinning long-term commercial strategies.
- Continuous monitoring of patent landscape updates is essential for navigating competitive and regulatory environments in South Korea.
Frequently Asked Questions (FAQs)
1. What is the primary innovation claimed in KR20200130334?
The innovation centers on a specific chemical compound, formulation, or method of administration that offers improved efficacy or stability over prior art, detailed within the independent claims.
2. How does this patent fit into South Korea’s pharmaceutical patent landscape?
It adds to Korea’s emphasis on protecting novel small molecules and biologic formulations, contributing to the nation’s robust IP environment aimed at fostering innovation in biotech and pharmaceuticals.
3. Can this patent be challenged or invalidated?
Yes. Challenges can be made through patent oppositions or litigation processes, particularly if prior art evidence demonstrates lack of novelty or inventive step.
4. How does the scope of claims influence commercialization strategies?
Broad claims provide extensive protection but risk validity; narrow claims ensure enforceability but may permit design-around strategies. Balancing the two is crucial for effective IP management.
5. Are there international counterparts of this patent?
It is likely that applicants filed similar applications in key jurisdictions such as the US, EU, and China to secure global protection for the invention.
References
- South Korean Intellectual Property Office (KIPO) - Patent Application Details
- Patent Landscape Reports – Global Pharmaceutical Patent Trends
- Patent Examiner Reports and Office Action Files (where accessible)
- International Patent Databases (WIPO PATENTSCOPE, Espacenet) for related filings
- Industry Reports on South Korea’s biotech patent activity
Note: Exact details—such as the applicant’s name, precise filing and publication dates, or specific claim language—should be verified via official patent databases for comprehensive assessment.
